Company Description
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases.
Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | John Quisel |
Contact Details
Address: 321 Arsenal Street, Suite 101 Watertown, Massachusetts 02472 United States | |
| Phone | 617 674 9274 |
| Website | discmedicine.com |
Stock Details
| Ticker Symbol | IRON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001816736 |
| ISIN Number | US2546041011 |
| Employer ID | 85-1613057 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John D. Quisel Esq., J.D., Ph.D. | Chief Executive Officer, President and Director |
| Dr. Donald William Nicholson Ph.D. | Executive Chairman |
| Dr. William Jacob Savage M.D., Ph.D. | Chief Medical Officer |
| Dr. Brian MacDonald ChB, MB, Ph.D. | Founder and Chair of Scientific Advisory Board |
| Jonathan Yu M.B.A. | Chief Opearating Officer |
| Dr. Rahul Rajan Kaushik Ph.D. | Chief Technical Officer |
| Dr. Rahul Khara J.D., Pharm.D. | General Counsel, Compliance Officer and Secretary |
| Srikanth Venkatraman Ph.D. | Senior Vice President and Head of Chemistry |
| Hua Yang Ph.D. | Senior Vice President and Head of Early Development and Clinical Pharmacology |
| Pamela Stephenson M.P.H. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | EFFECT | Notice of Effectiveness |
| Nov 15, 2024 | 424B5 | Filing |
| Nov 15, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 15, 2024 | 144 | Filing |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |